Genetic sequencing revealed unique mutations in TP53 and SMAD4, which were not previously reported in pancreatoblastoma but commonly seen in poorly differentiated neuroendocrine carcinomas and pancreatic ductal carcinomas [4, 5]. This evidence concerns the gene TP53 and Pancreatoblastoma.